Alex Zisson

Alex focuses on investments in the biopharmaceuticals industry, especially in pharmaceuticals, generics, drug delivery and specialty pharma and biotechnology. He joined H.I.G. Capital as a Managing Director in January 2016. He currently serves on the board of directors for Clarus Therapeutics, Leiter’s, Neurana Pharma, Taconic Biosciences and Arvelle Therapeutics.

Prior to H.I.G., Alex was spent 13 years making similar investments at Thomas, McNerney & Partners. Previous board seats included Auspex Pharmaceuticals (sold to Teva), InnoPharma (sold to Pfizer), Quinnova (sold to Amneal), Celator (public), Zogenix (public), Tranzyme (merged with Ocera) and observer roles at PCI Pharma Services (sold to Partners Group) and Coley Pharmaceutical (sold to Pfizer).

Prior to Thomas, McNerney, Alex spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan). During his tenure at H&Q, Alex led research teams covering the biotechnology, specialty pharmaceuticals, large-cap pharmaceuticals, drug delivery and diagnostics industries. After the merger of Chase H&Q and JPMorgan, Alex became the firm’s healthcare strategist. He was named twice in The Wall Street Journal All-Star Analysts Survey, including his last year at JPMorgan in which he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and ‘home run’ hitting (#8 across all industries).

Alex is the co-chair of the Business Advisory Council of the Children’s Tumor Foundation, an advisor for the Partnership Fund of NYC, which manages a bioaccelerator to advance local healthcare research, and is on the Life Sciences Council for Springboard Enterprises, a group that assists women entrepreneurs. He is also a board member for the Greenwich Council of the Boy Scouts of America.

He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.